Our data adds to a rapidly emerging body of evidence that a BRCA mutation may be associated with aberrancies in the OPG/RANK- signaling axis and may represent a potential therapeutic target for the non-surgical prevention of breast cancer in this high-risk population. The gene discussed is TNFRSF11A; the disease is breast carcinoma.